Abstract:: Cervical cancer remains a major global health challenge, particularly in lowand middle-income countries. Phytochemicals derived from medicinal plants exhibit potent anticancer, anti-inflammatory, and antioxidant properties. However, their therapeutic potential is often limited by poor solubility, low bioavailability, and rapid metabolism. Recent advances in nanotechnology have enabled the development of polymeric nanocarriers, such as polymeric nanoparticles, dendrimers, and liposomes, which significantly enhance the delivery and efficacy of phytoconstituents in cervical cancer therapy. These nanocarriers provide controlled drug release, site-specific targeting, and improved pharmacokinetics while minimizing systemic toxicity. Functionalization with targeting ligands further enhances cancer cell specificity, reducing off-target effects. Emerging research highlights the development of smart nanocarriers with stimuli-responsive release and codelivery systems to overcome multidrug resistance. Notable progress includes curcumin-, quercetin-, and resveratrol-loaded nanocarriers, which have demonstrated improved cytotoxicity and molecular targeting in preclinical studies. Furthermore, in silico approaches and systems pharmacology are increasingly employed to optimize nanocarrier design and predict therapeutic outcomes. Continued research focusing on clinical translation, largescale manufacturing, and regulatory validation is essential to bridge the gap between bench and bedside. Polymeric nanocarriers thus represent a transformative strategy for delivering phytochemicals in cervical cancer therapy, offering promising avenues for effective, personalized, and less toxic treatment alternatives.
Pandey et al. (Thu,) studied this question.